Business
Ondine shortlisted for HSJ Partnership Award
Ondine Biomedical Inc. has been shortlisted for a prestigious HSJ Partnership Award alongside Mid Yorkshire Teaching NHS Trust for their work in reducing post-surgical infection rates with Ondine's Steriwave® technology. This collaboration demonstrated a 71% reduction in surgical site infections over six months, with independent analysis by the York Health Economics Consortium estimating potential annual savings of up to £200 million across UK hospitals, as Steriwave offers an antibiotic-sparing alternative to mupirocin and generates £1.49 to £2.38 in savings for every £1 spent on preventing surgical site infections. Disclaimer*
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n16 December 2025\nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\n \nOndine shortlisted for HSJ Partnership Award\n \nHSJ Partnership Award Finalists: Ondine Biomedical and Mid Yorkshire Teaching NHS Trust for Cutting Post-surgical Infection Rates\n \nOndine Biomedical Inc. (AIM: OBI) and Mid Yorkshire Teaching NHS Trust (Mid Yorks) have been shortlisted for the 'Most Impactful Use of Technology on Clinical Practice' award at the prestigious 2026 HSJ Partnership Awards, following the successful implementation of Ondine's Steriwave® nasal decolonisation technology.\n \nThis award recognises the exceptional contributions from companies and technology partners that work with NHS organisations to implement solutions that are delivering meaningful improvements in clinical practice and patient outcomes.\n \nIntroduced to reduce surgical site infections (SSI) in patients undergoing hip and knee replacement surgeries at Mid Yorks' Pontefract and Pinderfields hospitals, the Steriwave intervention was associated with a 71% reduction in SSI over a six-month period, along with significant cost savings and tangible improvements in patient outcomes.\nSince the initial pilot, a number of major hospitals across England are using or evaluating Steriwave across multiple specialties, including ENT, neurosurgery, cardiac, orthopaedic, and spinal surgery, as well as in the ICU, where immunocompromised patients are particularly vulnerable to infection.\nGrowing recognition of the importance of nasal decolonisation-with the nose a major reservoir of pathogens-has coincided with rising antimicrobial resistance, which is reducing the effectiveness of mupirocin, the current standard of care. Mupirocin also has poor compliance, requiring twice-daily application for five days prior to surgery. In contrast, a single pre-operative Steriwave treatment rapidly destroys all classes of pathogens without generating resistance, offering an effective, antibiotic-sparing alternative.\nReal-world data from Mid Yorks demonstrated that, in a standardised cohort of 1,000 people, Steriwave prevents an additional 9.8 SSIs compared to standard of care alone and reduces total hospital bed days by 139. Using this data, an independent health-economic analysis by the York Health Economics Consortium (YHEC) found that...